Xintela AB (publ) (XINT.ST)
SEK 0.35
(-8.42%)
SEK 0.35
(-8.42%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 57.31 Million SEK | -19.98% |
| 2022 | 69.06 Million SEK | 58.56% |
| 2021 | 43.55 Million SEK | 28.49% |
| 2020 | 33.89 Million SEK | -10.99% |
| 2019 | 38.08 Million SEK | 47.43% |
| 2018 | 25.83 Million SEK | 17.77% |
| 2017 | 21.93 Million SEK | 28.27% |
| 2016 | 17.1 Million SEK | 39.35% |
| 2015 | 12.27 Million SEK | 64.68% |
| 2014 | 7.45 Million SEK | 233.25% |
| 2013 | 2.23 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 10.88 Million SEK | -9.45% |
| 2024 Q2 | 10.39 Million SEK | -4.52% |
| 2023 Q1 | 15.2 Million SEK | -34.53% |
| 2023 Q4 | 12.02 Million SEK | -2.25% |
| 2023 FY | 55.26 Million SEK | -19.98% |
| 2023 Q3 | 12.3 Million SEK | -29.9% |
| 2023 Q2 | 17.55 Million SEK | 15.41% |
| 2022 Q4 | 23.22 Million SEK | 87.11% |
| 2022 Q3 | 12.41 Million SEK | -28.8% |
| 2022 Q2 | 17.43 Million SEK | 9.04% |
| 2022 Q1 | 15.98 Million SEK | 31.94% |
| 2022 FY | 69.06 Million SEK | 58.56% |
| 2021 FY | 43.55 Million SEK | 28.49% |
| 2021 Q4 | 12.11 Million SEK | 12.1% |
| 2021 Q1 | 8.93 Million SEK | -20.1% |
| 2021 Q3 | 10.81 Million SEK | -7.58% |
| 2021 Q2 | 11.69 Million SEK | 30.97% |
| 2020 FY | 33.89 Million SEK | -10.99% |
| 2020 Q1 | 7.51 Million SEK | -24.85% |
| 2020 Q3 | 7.06 Million SEK | -13.22% |
| 2020 Q4 | 11.17 Million SEK | 58.25% |
| 2020 Q2 | 8.13 Million SEK | 8.27% |
| 2019 Q4 | 10 Million SEK | 25.61% |
| 2019 Q3 | 7.96 Million SEK | -25.28% |
| 2019 Q2 | 10.65 Million SEK | 12.63% |
| 2019 Q1 | 9.46 Million SEK | 8.51% |
| 2019 FY | 38.08 Million SEK | 47.43% |
| 2018 FY | 25.83 Million SEK | 17.77% |
| 2018 Q4 | 8.72 Million SEK | 90.43% |
| 2018 Q3 | 4.57 Million SEK | -5.82% |
| 2018 Q2 | 4.86 Million SEK | -36.63% |
| 2018 Q1 | 7.67 Million SEK | 15.8% |
| 2017 Q4 | 6.62 Million SEK | 35.62% |
| 2017 FY | 21.93 Million SEK | 28.27% |
| 2017 Q1 | 5.41 Million SEK | 17.15% |
| 2017 Q2 | 5.01 Million SEK | -7.28% |
| 2017 Q3 | 4.88 Million SEK | -2.61% |
| 2016 FY | 17.1 Million SEK | 39.35% |
| 2016 Q1 | 3.62 Million SEK | -30.68% |
| 2016 Q4 | 4.61 Million SEK | 52.56% |
| 2016 Q3 | 3.02 Million SEK | -42.21% |
| 2016 Q2 | 5.23 Million SEK | 44.42% |
| 2015 Q3 | 2.12 Million SEK | -25.06% |
| 2015 Q2 | 2.83 Million SEK | 15.26% |
| 2015 Q1 | 2.45 Million SEK | 0.0% |
| 2015 FY | 12.27 Million SEK | 64.68% |
| 2015 Q4 | 5.23 Million SEK | 146.44% |
| 2014 FY | 7.45 Million SEK | 233.25% |
| 2013 FY | 2.23 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Simris Alg AB (publ) | 38.64 Million SEK | -48.326% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 82.173% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 83.973% |
| Active Biotech AB (publ) | 44.8 Million SEK | -27.912% |
| Amniotics AB (publ) | 29.07 Million SEK | -97.152% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -291.155% |
| BioArctic AB (publ) | 89.62 Million SEK | 36.051% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 96.215% |
| Camurus AB (publ) | 1.05 Billion SEK | 94.591% |
| Cantargia AB (publ) | 290.01 Million SEK | 80.237% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -161.777% |
| CombiGene AB (publ) | 44.14 Million SEK | -29.838% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 59.915% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -102.342% |
| Genovis AB (publ.) | 88.19 Million SEK | 35.014% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 50.192% |
| Mendus AB (publ) | 129.13 Million SEK | 55.616% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -688.608% |
| Intervacc AB (publ) | 79.78 Million SEK | 28.162% |
| Kancera AB (publ) | 63.07 Million SEK | 9.133% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -938.521% |
| LIDDS AB (publ) | 27.75 Million SEK | -106.529% |
| Lipum AB (publ) | 37.3 Million SEK | -53.633% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -690.13% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 57.829% |
| NextCell Pharma AB | -576.01 Thousand SEK | 10050.366% |
| OncoZenge AB (publ) | 15.9 Million SEK | -260.365% |
| Saniona AB (publ) | 1.07 Million SEK | -5221.82% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 68.462% |
| Ziccum AB (publ) | 27.87 Million SEK | -105.596% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -249.466% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 81.336% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | -34.444% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -224.131% |
| Corline Biomedical AB | 30.16 Million SEK | -89.989% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 1.232% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 31.085% |
| Aptahem AB (publ) | 10.01 Million SEK | -472.419% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 57.447% |
| Fluicell AB (publ) | 28.61 Million SEK | -100.287% |
| Biovica International AB (publ) | 133.72 Million SEK | 57.138% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -189.621% |
| AcouSort AB (publ) | 25.87 Million SEK | -121.503% |
| Abliva AB (publ) | 27.86 Million SEK | -105.684% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 70.379% |
| 2cureX AB (publ) | 36.51 Million SEK | -56.953% |
| I-Tech AB | 40.14 Million SEK | -42.762% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 93.331% |
| Cyxone AB (publ) | 28.21 Million SEK | -103.147% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 47.593% |
| Biosergen AB | 26.8 Million SEK | -113.794% |
| Nanologica AB (publ) | 69.88 Million SEK | 17.988% |
| SynAct Pharma AB | 224.49 Million SEK | 74.469% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | -29.745% |
| BioInvent International AB (publ) | 441.4 Million SEK | 87.015% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -139.273% |
| Alzinova AB (publ) | 36.39 Million SEK | -57.479% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 80.219% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -629.558% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 48.324% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -289.905% |